

CHEAT SHEET
for digital health leaders

Generative Artificial Intelligence

Published - March 2023 • 5-min read

Key takeaways

- The field of generative AI is not new, but recent high-profile advancements in performance and increased funding mean it's likely to impact healthcare soon.
- Generative AI could transform healthcare in a variety of ways, going beyond chatbots to include search, image creation, and even synthetic data.
- Bias and misinformation are the two biggest obstacles to generative AI that could limit early use cases to non-clinical functions where they are less likely to cause harm.

What is it?

Generative artificial intelligence (AI) is a subset of machine learning that describes algorithms that create new content. This ability to generate new content distinguishes generative AI models from retrieval-based models and predictive AI.

The most common generative AI models today are text-based. These models, known as large language models, have been trained on enormous data sets in a manner that allows them to both understand input text and create responses. However, generative can be used for much more than just text. These algorithms can also be built to create images, code, and even synthetic data.

Most of today's generative AI models are still in the research and development stage, meaning there is not widespread commercial usage beyond pilot projects. The one growing exception here is with a few large language models. The most widely known example of generative AI is OpenAI's ChatGPT, a publicly available chatbot service that Microsoft recently incorporated into Bing search. Not to be out done, Alphabet (the parent company of Google) released Bard, its own generative AI-powered conversational search in February of 2023.

Potential health care use cases



Expanding the scope of asynchronous telehealth and triage tools



Utilizing synthetic data in drug discovery and clinical trials



Integrating disparate data sets to identify rising-risk populations earlier



Summarizing medical conversations in plain language for patients

Why does it matter?

The basics of these generative AI models, particularly text-based models, have been around for years. Now, advancements in training are showing that this technology could be ready for use across a variety of fields in the next few years.

Notably, recent studies of OpenAI's ChatGPT and Google's Med-PaLM have highlighted the potential for these models to be used for healthcare purposes. A December 2022 [study](#) led by Google researchers found that Med-PaLM performed as good or only slightly worse than clinicians across three areas: comprehension of inputs, correct retrieval of information, and correct reasoning. And in February, a [study](#) found that ChatGPT could perform at or near the 60% accuracy threshold required to pass the U.S. Medical Licensing Exam.

These studies demonstrate that we are much closer to real-world impact than many healthcare leaders might think. For example, imagine an AI tool that could take a patient's medical history and write a quick summary paragraph that highlights the most relevant parts for the clinician. That could simultaneously improve patient care and the clinician workflow. And this is just one type of generative AI — the potential image and data creation capabilities indicate there will be wide-ranging applications in medical imaging and synthetic data as well.

Potential key impacts of generative AI in healthcare



Faster, cheaper drug discovery



Improved clinician workflows



Better patient experience through support tools



Expanded access to care via digital therapeutics

Finally, investors clearly see generative AI as a key future technology. According to CB Insights, startups focused on generative AI received \$2.6 billion in funding in 2022, up from just \$271M in 2020. And this area is primed for continued investment, as over two-thirds of generative AI companies have yet to go through a Series A round of funding.

Source: CB Insights; Kung TH, et al., "Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models," *PLOS Digital Health*, Feb 2023; Singhal K, et al., "Large Language Models Encode Clinical Knowledge," *Google Research, Deep Mind*, Dec 2022.

How does it work?

Generative AI goes beyond just identifying and classifying patterns (predictive AI) and creates something new that resembles the learned pattern. Take, for example, a set of images of chest X-rays. A predictive AI tool might be able to sort through these and classify the findings as normal versus abnormal. A generative AI tool would be able to create a new example of a “abnormal” chest X-ray, perhaps for training purposes.

When applied to chat, this capability has the potential to transform the scope and usefulness of conversations. Many chatbots in use today are at least partially retrieval-based, meaning the responses from these chatbots are bounded by the phrases and sentences the chatbot already knows. As researchers who have compared the performance of retrieval-based chatbots to generative chatbots have shown, this limits the ability of retrieval-based chatbots to provide useful information outside of the narrow scope of potential conversations. Generative chatbots have no such limitations, as they can generate new sentences that are based on the vast amount of text they have been trained on.

However, the potential expanded scope introduces significant risk, particularly in bias and misinformation. These models leverage self-supervised learning on vast amounts of data to be able to create realistic generated responses. But this type of training can lead the models to potentially provide incorrect or misleading information. It also means that these models will reproduce racial and gender stereotypes and reflect existing biases within medicine. If these drawbacks cannot be accounted for, they could delay the use of many of these generative AI tools for clinical purposes.

Conversations you should be having

01

Start your conversation by discussing the major problems facing your organization and then work backward to how generative AI can help, instead of starting with a discussion of use cases.

02

Prepare for future decisions around when an AI model is accurate enough, including weighing potential benefits of being an early mover against potential drawbacks of failure.

03


Decide how your organization can monitor future technological developments in generative AI.

04


Determine how to communicate with and respond to patients and other stakeholders who may utilize third-party generative AI tools outside of your organization.

Related content


Advisory Board resources

 CHEAT SHEET
AI in health care


[Read now](#)

 PODCAST
Microsoft's head of AI on building ethical systems


[Read now](#)

 WEBINAR
2022 Analytics and AI survey


[Read now](#)

 INFOGRAPHIC
How to combat AI bias

[Read now](#)

 OUR TAKE
How AI and automation can help clinicians practice at top of license

[Read now](#)

 RESEARCH
How plans are (and aren't) using AI to automate prior authorizations

[Read now](#)

Project director

Ty Aderhold

aderholm@advisory.com

Program leadership

John League

LEGAL CAVEAT

Advisory Board has made efforts to verify the accuracy of the information it provides to members. This report relies on data obtained from many sources, however, and Advisory Board cannot guarantee the accuracy of the information provided or any analysis based thereon. In addition, Advisory Board is not in the business of giving legal, medical, accounting, or other professional advice, and its reports should not be construed as professional advice. In particular, members should not rely on any legal commentary in this report as a basis for action, or assume that any tactics described herein would be permitted by applicable law or appropriate for a given member's situation. Members are advised to consult with appropriate professionals concerning legal, medical, tax, or accounting issues, before implementing any of these tactics. Neither Advisory Board nor its officers, directors, trustees, employees, and agents shall be liable for any claims, liabilities, or expenses relating to (a) any errors or omissions in this report, whether caused by Advisory Board or any of its employees or agents, or sources or other third parties, (b) any recommendation or graded ranking by Advisory Board, or (c) failure of member and its employees and agents to abide by the terms set forth herein.

Advisory Board and the "A" logo are registered trademarks of The Advisory Board Company in the United States and other countries. Members are not permitted to use these trademarks, or any other trademark, product name, service name, trade name, and logo of Advisory Board without prior written consent of Advisory Board. All other trademarks, product names, service names, trade names, and logos used within these pages are the property of their respective holders. Use of other company trademarks, product names, service names, trade names, and logos or images of the same does not necessarily constitute (a) an endorsement by such company of Advisory Board and its products and services, or (b) an endorsement of the company or its products or services by Advisory Board. Advisory Board is not affiliated with any such company.

IMPORTANT: Please read the following.

Advisory Board has prepared this report for the exclusive use of its members. Each member acknowledges and agrees that this report and the information contained herein (collectively, the "Report") are confidential and proprietary to Advisory Board. By accepting delivery of this Report, each member agrees to abide by the terms as stated herein, including the following:

1. Advisory Board owns all right, title, and interest in and to this Report. Except as stated herein, no right, license, permission, or interest of any kind in this Report is intended to be given, transferred to, or acquired by a member. Each member is authorized to use this Report only to the extent expressly authorized herein.
2. Each member shall not sell, license, republish, or post online or otherwise this Report, in part or in whole. Each member shall not disseminate or permit the use of, and shall take reasonable precautions to prevent such dissemination or use of, this Report by (a) any of its employees and agents (except as stated below), or (b) any third party.
3. Each member may make this Report available solely to those of its employees and agents who (a) are registered for the workshop or membership program of which this Report is a part, (b) require access to this Report in order to learn from the information described herein, and (c) agree not to disclose this Report to other employees or agents or any third party. Each member shall use, and shall ensure that its employees and agents use, this Report for its internal use only. Each member may make a limited number of copies, solely as adequate for use by its employees and agents in accordance with the terms herein.
4. Each member shall not remove from this Report any confidential markings, copyright notices, and/or other similar indicia herein.
5. Each member is responsible for any breach of its obligations as stated herein by any of its employees or agents.
6. If a member is unwilling to abide by any of the foregoing obligations, then such member shall promptly return this Report and all copies thereof to Advisory Board.



655 New York Avenue NW, Washington DC 20001
202-266-5600 | advisory.com